^
    1d
    Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    purinostat
    1d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    1d
    GLO-PACT: Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, American University of Beirut Medical Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Columvi (glofitamab-gxbm)
    1d
    Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    2d
    XBP1-driven proliferative B cell subcluster in Diffuse Large B Cell Lymphoma linked to altered nucleotide metabolism. (PubMed, Eur J Med Res)
    This analysis has identified and characterized the proliferation-related B cells in DLBCL, which may provide some ideas for the treatment strategies in immune-oncology and cellular therapies.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • XBP1 (X-box-binding protein 1)
    2d
    Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL. (PubMed, Blood Rev)
    Recently, ADCs have expanded the DLBCL therapeutic landscape, with the approvals of CD79b-targeted polatuzumab vedotin and CD19-directed loncastuximab tesirine for R/R and even frontline disease. However, the clinical application of ADCs is accompanied by challenges, including the management of characteristic toxicities, understanding and overcoming mechanisms of resistance. This review systematically synthesizes the mechanisms of action, updated clinical evidence, toxicity profiles, and resistance mechanisms of ADCs in DLBCL, while also discusses management strategies and provides perspectives on future directions.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
    |
    Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq)
    3d
    Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine. (PubMed, Discov Oncol)
    This review systematically summarizes the core mechanisms by which EBV contributes to lymphoma pathogenesis and evaluates the breakthroughs and challenges of current therapeutic strategies. It also outlines the future directions of precision medicine, based on multi-disciplinary integration, to enhance the understanding of the molecular pathology of EBV-associated lymphomas and optimize personalized treatment.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    3d
    XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells. (PubMed, Hematology)
    Cell lines representing DLBCL subtypes were treated with varying concentrations of the XPO1 inhibitor selinexor (XPO1i), cisplatin (CDDP), and oxaliplatin (OXA), alone or in combination. In OCI-Ly8 and OCI-Ly1 cells, OXA alone inhibited phosphorylation of AKT and mTOR while increasing phosphorylation of JNK, ATM, and p53, and expression of γH2AX; these effects were potentiated by the combination of XPO1i and OXA. XPO1 inhibition enhances platinum-induced cytotoxicity in GCB-DLBCL, supporting clinical evaluation of XPO1i-platinum combinations as salvage therapy.
    Journal • IO biomarker
    |
    XPO1 (Exportin 1)
    |
    cisplatin • oxaliplatin • Xpovio (selinexor)
    3d
    CS22-03: Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (clinicaltrials.gov)
    P=N/A, N=30, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed
    Trial completion
    4d
    CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Columvi (glofitamab-gxbm)
    4d
    Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse Large B-Cell Lymphoma. (PubMed, Cancer Med)
    These results suggest that clonal complexity captures tumor-intrinsic features and biological diversity in DLBCL, especially in the ABC subtype, offering novel insights into the disease pathogenesis.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IRF4 (Interferon regulatory factor 4) • IFNA1 (Interferon Alpha 1)